Ivosidenib enhances cisplatin sensitivity in ovarian cancer by reducing cancer cell stemness

Abstract

Aim: Cancer stem cells (CSCs) are pivotal in mediating platinum resistance in ovarian cancer. This study aimed to screen compounds sensitizing CSCs to cisplatin by using a small molecule inhibitor library.

Methods: A library of 105 common drugs was screened in ovarian CSC model SK-3rd and ovarian cancer platinum-resistant cell model SKDDP to identify those that could enhance sensitivity to cisplatin by MTT assay. The antitumor effect was assessed in ovarian cancer cells using the MTT assay, colony formation assay, and apoptosis assay. The impact on cancer cell stemness was evaluated using qPCR and Sphere-forming assays. Finally, the effect of the combination regimen was evaluated in patient-derived organoids (PDOs) under different treatments by the CellTiter-Glo Luminescence Assay.

Results: The results of the initial screening on SK-3rd identified five candidate compounds. Rescreening on SKDDP showed that Ivosidenib was the most effective in sensitizing cisplatin. MTT, colony formation, and apoptosis assays demonstrated that Ivosidenib enhanced the sensitivity to cisplatin, inhibited proliferation, and induced apoptosis in ovarian cancer cells, including SK-3rd and SKDDP. Furthermore, Ivosidenib lowered stemness marker expression and countered CSC enrichment caused by platinum-based chemotherapy in ovarian cancer cells. Finally, the synergistic effect of this combination was also confirmed in three ovarian cancer PDOs.

Conclusion: Ivosidenib may increase cisplatin sensitivity in ovarian cancer cells by decreasing their stemness, providing a potential therapeutic method for ovarian cancer patients.

Keywords

Ivosidenib / cancer stem cells / platinum resistance / organoids

References

[1] Siegel RL,Fuchs HE.Cancer statistics, 2021.CA Cancer J Clin2021;71:7-33

[2] Tsibulak I,Marth C.Hopes and failures in front-line ovarian cancer therapy.Crit Rev Oncol Hematol2019;143:14-9

[3] Davis A,Friedlander M."Platinum resistant" ovarian cancer: what is it, who to treat and how to measure benefit?.Gynecol Oncol2014;133:624-31

[4] Batlle E.Cancer stem cells revisited.Nat Med2017;23:1124-34

[5] Chu X,Ning J.Cancer stem cells: advances in knowledge and implications for cancer therapy.Signal Transduct Target Ther2024;9:170 PMCID:PMC11224386

[6] Alison MR,Nicholson LJ.Cancer stem cells: problems for therapy?.J Pathol2011;223:147-61

[7] Dean M,Bates S.Tumour stem cells and drug resistance.Nat Rev Cancer2005;5:275-84

[8] Visvader JE.Cancer stem cells in solid tumours: accumulating evidence and unresolved questions.Nat Rev Cancer2008;8:755-68

[9] Chebouti I,Wimberger P.Analysis of disseminated tumor cells before and after platinum based chemotherapy in primary ovarian cancer. Do stem cell like cells predict prognosis?.Oncotarget2016;7:26454-64 PMCID:PMC5041992

[10] Thakur B.Cisplatin triggers cancer stem cell enrichment in platinum-resistant cells through NF-κB-TNFα-PIK3CA loop.J Exp Clin Cancer Res2017;36:164 PMCID:PMC5701448

[11] Hosonuma S,Kojo S.Clinical significance of side population in ovarian cancer cells.Hum Cell2011;24:9-12 PMCID:PMC3051070

[12] Zheng C,Li Y.Donafenib and GSK-J4 synergistically induce ferroptosis in liver cancer by upregulating HMOX1 expression.Adv Sci (Weinh)2023;10:e2206798.[

[13] Li GN,Wang Z.Elaiophylin triggers paraptosis and preferentially kills ovarian cancer drug-resistant cells by inducing MAPK hyperactivation.Signal Transduct Target Ther2022;7:317 PMCID:PMC9468165

[14] Mellinghoff IK,Touat M.Ivosidenib in Isocitrate Dehydrogenase 1-Mutated Advanced Glioma.J Clin Oncol2020;38:3398-406

[15] Montesinos P,Vives S.Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia.N Engl J Med2022;386:1519-31

[16] Popovici-Muller J,Artin E.Discovery of AG-120 (Ivosidenib): a first-in-class mutant IDH1 inhibitor for the treatment of IDH1 mutant cancers.ACS Med Chem Lett2018;9:300-5

[17] Mellinghoff IK,Wen PY.Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial.Nat Med2023;29:615-22 PMCID:PMC10313524

[18] Wen Y,Yi X.EZH2 activates CHK1 signaling to promote ovarian cancer chemoresistance by maintaining the properties of cancer stem cells.Theranostics2021;11:1795-813 PMCID:PMC7778604

[19] Tao L,Pan X.Repression of LSD1 potentiates homologous recombination-proficient ovarian cancer to PARP inhibitors through down-regulation of BRCA1/2 and RAD51.Nat Commun2023;14:7430 PMCID:PMC10654398

[20] Weiswald LB,Dangles-Marie V.Spherical cancer models in tumor biology.Neoplasia2015;17:1-15 PMCID:PMC4309685

[21] Neal JT,Zhu J.Organoid modeling of the tumor immune microenvironment.Cell2018;175:1972-1988.e16 PMCID:PMC6656687

[22] Dijkstra KK,Weeber F.Generation of tumor-reactive T cells by co-culture of peripheral blood lymphocytes and tumor organoids.Cell2018;174:1586-1598.e12 PMCID:PMC6558289

[23] Moore KN,Hamilton EP.Adavosertib with chemotherapy in patients with primary platinum-resistant ovarian, fallopian tube, or peritoneal cancer: an open-label, four-arm, phase II study.Clin Cancer Res2022;28:36-44

[24] Yuan G,Zheng H.Suvemcitug plus chemotherapy for platinum-resistant epithelial ovarian, fallopian tube and primary peritoneal cancer: a phase 1b dose-escalation trial.Gynecol Oncol2024;187:212-20

[25] Rowe JM.Progress and predictions: AML in 2018.Best Pract Res Clin Haematol2018;31:337-40

[26] Lavacchi D,Rossi G.Ivosidenib in IDH1-mutated cholangiocarcinoma: Clinical evaluation and future directions.Pharmacol Ther2022;237:108170

[27] Yang H,Guan KL.IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives.Clin Cancer Res2012;18:5562-71

[28] Zhang C,Yang C.Wild-type IDH1 maintains NSCLC stemness and chemoresistance through activation of the serine biosynthetic pathway.Sci Transl Med2023;15:eade4113

[29] Vecht CJ,Wilms EB.Interactions between antiepileptic and chemotherapeutic drugs.Lancet Neurol2003;2:404-9

[30] Lu P,Zhang C,Wang X.An aggregation-induced emission fluorescence probe for evaluating the effect of CYP450 changes under tumor chemotherapy.Talanta2022;239:123111

[31] Bompart G.Cisplatin-induced changes in cytochrome P-450, lipid peroxidation and drug-metabolizing enzyme activities in rat kidney cortex.Toxicol Lett1989;48:193-9

[32] Dinh A,Kontoyiannis DP.Ivosidenib significantly reduces triazole levels in patients with acute myeloid leukemia and myelodysplastic syndrome.Cancer2024;130:1964-71

[33] Bolleddula J,Yang H.PBPK modeling to predict drug-drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction.CPT Pharmacometrics Syst Pharmacol2021;10:577-88 PMCID:PMC8213421

[34] Zhang C,Gao X.Platinum-based drugs for cancer therapy and anti-tumor strategies.Theranostics2022;12:2115-32 PMCID:PMC8899578

[35] Mizuno T,Ishikawa K.Significance of downregulation of renal organic cation transporter (SLC47A1) in cisplatin-induced proximal tubular injury.Onco Targets Ther2015;8:1701-6 PMCID:PMC4506035

[36] Chen H,Li H.NBS1 lactylation is required for efficient DNA repair and chemotherapy resistance.Nature2024;631:663-9 PMCID:PMC11254748

[37] Eijck CWF, Vadgama D, van Eijck CHJ, Wilmink JW; Dutch Pancreatic Cancer Group (DPCG). Metformin boosts antitumor immunity and improves prognosis in upfront resected pancreatic cancer: an observational study.J Natl Cancer Inst2024;116:1374-83 PMCID:PMC11308183

[38] Tang Y,Hu W.Effect of edaravone on radiation-induced brain necrosis in patients with nasopharyngeal carcinoma after radiotherapy: a randomized controlled trial.J Neurooncol2014;120:441-7 PMCID:PMC4220954